Waldman AD, Fritz JM, Lenardo MJ. A guide to cancer immunotherapy: from T cell basic science to clinical practice. Nat Rev Immunol. 2020;20(11):651–68. https://doi.org/10.1038/s41577-020-0306-5.

Article  CAS  PubMed  PubMed Central  Google Scholar 

The Nobel Prize in Physiology or Medicine. 2018 https://www.nobelprize.org/uploads/2018/10/press-medicine2018.pdf Accessed 2024-02-08.

Khan S, Gerber DE. Autoimmunity, checkpoint inhibitor therapy and immune-related adverse events: a review. Semin Cancer Biol. 2020;64:93–101. https://doi.org/10.1016/j.semcancer.2019.06.012.

Article  CAS  PubMed  Google Scholar 

Yoshikawa Y, Imamura M, Yamauchi M, Hayes CN, Aikata H, Okamoto W, et al. Prevalence of immune-related adverse events and anti-tumor efficacy following immune checkpoint inhibitor therapy in Japanese patients with various solid tumors. BMC Cancer. 2022;22(1):1232. https://doi.org/10.1186/s12885-022-10327-7.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Bertrand A, Kostine M, Barnetche T, Truchetet ME, Schaeverbeke T. Immune related adverse events associated with anti-CTLA-4 antibodies: systematic review and meta-analysis. BMC Med. 2015;13:211. https://doi.org/10.1186/s12916-015-0455-8.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wang PF, Chen Y, Song SY, Wang TJ, Ji WJ, Li SW, et al. Immune-related adverse events associated with anti-PD-1/PD-L1 treatment for malignancies: a meta-analysis. Front Pharmacol. 2017;8:730. https://doi.org/10.3389/fphar.2017.00730.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Martins F, Sofiya L, Sykiotis GP, Lamine F, Maillard M, Fraga M, et al. Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance. Nat Rev Clin Oncol. 2019;16(9):563–80. https://doi.org/10.1038/s41571-019-0218-0.

Article  CAS  PubMed  Google Scholar 

Garon EB, Rizvi NA, Hui R, Leighl N, Balmanoukian AS, Eder JP, et al. Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med. 2015;372(21):2018–28. https://doi.org/10.1056/NEJMoa1501824.

Article  PubMed  Google Scholar 

Eigentler TK, Hassel JC, Berking C, Aberle J, Bachmann O, Grünwald V, et al. Diagnosis, monitoring and management of immune-related adverse drug reactions of anti-PD-1 antibody therapy. Cancer Treat Rev. 2016;45:7–18. https://doi.org/10.1016/j.ctrv.2016.02.003.

Article  CAS  PubMed  Google Scholar 

Wolchok JD, Chiarion-Sileni V, Gonzalez R, Rutkowski P, Grob JJ, Cowey CL et al. Overall survival with combined Nivolumab and Ipilimumab in advanced Melanoma. N Engl J Med. 2017;377(14):1345–1356. doi: 10.1056/NEJMoa1709684. Epub 2017 Sep 11. Erratum in: N Engl J Med. 2018;379(22):2185.

Hodi FS, Chesney J, Pavlick AC, Robert C, Grossmann KF, McDermott DF, et al. Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial. Lancet Oncol. 2016;17(11):1558–68. https://doi.org/10.1016/S1470-2045(16)30366-7.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lisberg A, Tucker DA, Goldman JW, Wolf B, Carroll J, Hardy A, et al. Treatment-related adverse events predict improved clinical outcome in NSCLC patients on KEYNOTE-001 at a single Center. Cancer Immunol Res. 2018;6(3):288–94. https://doi.org/10.1158/2326-6066.CIR-17-0063.

Article  PubMed  PubMed Central  Google Scholar 

Fujii T, Colen RR, Bilen MA, Hess KR, Hajjar J, Suarez-Almazor ME, et al. Incidence of immune-related adverse events and its association with treatment outcomes: the MD Anderson Cancer Center experience. Invest New Drugs. 2018;36(4):638–46. https://doi.org/10.1007/s10637-017-0534-0.

Article  CAS  PubMed  Google Scholar 

Esfahani K, Meti N, Miller WH Jr, Hudson M. Adverse events associated with immune checkpoint inhibitor treatment for cancer. CMAJ. 2019;191(2):E40–6. https://doi.org/10.1503/cmaj.180870.

Article  PubMed  PubMed Central  Google Scholar 

Lopci E, Hicks RJ, Dimitrakopoulou-Strauss A, Dercle L, Iravani A, Seban RD, et al. Joint EANM/SNMMI/ANZSNM practice guidelines/procedure standards on recommended use of [18F]FDG PET/CT imaging during immunomodulatory treatments in patients with solid tumors version 1.0. Eur J Nucl Med Mol Imaging. 2022;49(7):2323–41. https://doi.org/10.1007/s00259-022-05780-2.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Cherk MH, Nadebaum DP, Barber TW, Beech P, Haydon A, Yap KS. 18 F-FDG PET/CT features of immune-related adverse events and pitfalls following immunotherapy. J Med Imaging Radiat Oncol. 2022;66(4):483–94. https://doi.org/10.1111/1754-9485.13390.

Article  PubMed  PubMed Central  Google Scholar 

Lang N, Dick J, Slynko A, Schulz C, Dimitrakopoulou-Strauss A, Sachpekidis C, et al. Clinical significance of signs of autoimmune colitis in 18F-fluorodeoxyglucose positron emission tomography-computed tomography of 100 stage-IV melanoma patients. Immunotherapy. 2019;11(8):667–76. https://doi.org/10.2217/imt-2018-0146.

Article  CAS  PubMed  Google Scholar 

Sachpekidis C, Kopp-Schneider A, Hassel JC, Dimitrakopoulou-Strauss A. Assessment of early metabolic progression in melanoma patients under immunotherapy: an 18F-FDG PET/CT study. EJNMMI Res. 2021;11(1):89. Published 2021 Sep 8. https://doi.org/10.1186/s13550-021-00832-4

Michielin O, van Akkooi ACJ, Ascierto PA, Dummer R, Keilholz U, ESMO Guidelines Committee. Cutaneous melanoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up†. Ann Oncol. 2019;30(12):1884–901. https://doi.org/10.1093/annonc/mdz411.

Article  CAS  PubMed  Google Scholar 

Keilholz U, Ascierto PA, Dummer R, Robert C, Lorigan P, van Akkooi A, et al. ESMO consensus conference recommendations on the management of metastatic melanoma: under the auspices of the ESMO Guidelines Committee. Ann Oncol. 2020;31(11):1435–48. https://doi.org/10.1016/j.annonc.2020.07.004.

Article  CAS  PubMed  Google Scholar 

Michielin O, van Akkooi A, Lorigan P, Ascierto PA, Dummer R, Robert C, et al. ESMO consensus conference recommendations on the management of locoregional melanoma: under the auspices of the ESMO Guidelines Committee. Ann Oncol. 2020;31(11):1449–61. https://doi.org/10.1016/j.annonc.2020.07.005.

Article  CAS  PubMed  Google Scholar 

Remon J, Soria JC, Peters S, ESMO Guidelines Committee. Early and locally advanced non-small-cell lung cancer: an update of the ESMO Clinical Practice Guidelines focusing on diagnosis, staging, systemic and local therapy. Ann Oncol. 2021;32(12):1637–42. https://doi.org/10.1016/j.annonc.2021.08.1994.

Article  CAS  PubMed  Google Scholar 

Hendriks LE, Kerr KM, Menis J, Mok TS, Nestle U, Passaro A, et al. Non-oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2023;34(4):358–76. https://doi.org/10.1016/j.annonc.2022.12.013.

Article  CAS  PubMed  Google Scholar 

Hendriks LE, Kerr KM, Menis J, Mok TS, Nestle U, Passaro A, et al. Oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2023;34(4):339–57. https://doi.org/10.1016/j.annonc.2022.12.009.

Article  CAS  PubMed  Google Scholar 

Haanen JBAG, Carbonnel F, Robert C et al. Management of toxicities from immunotherapy: ESMO clinical practice guidelines for diagnosis, treatment and follow-up [published correction appears in Ann Oncol. 2018;29(Suppl 4):iv264-iv266]. Ann Oncol. 2017;28(suppl_4):iv119-iv142. https://doi.org/10.1093/annonc/mdx225

Haanen J, Obeid M, Spain L, Carbonnel F, Wang Y, Robert C, et al. Management of toxicities from immunotherapy: ESMO clinical practice guideline for diagnosis, treatment and follow-up. Ann Oncol. 2022;33(12):1217–38. https://doi.org/10.1016/j.annonc.2022.10.001.

Article  CAS  PubMed  Google Scholar 

Boellaard R, Delgado-Bolton R, Oyen WJ, Giammarile F, Tatsch K, Eschner W, et al. FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0. Eur J Nucl Med Mol Imaging. 2015;42(2):328–54. https://doi.org/10.1007/s00259-014-2961-x.

Article  CAS  PubMed  Google Scholar 

Thoeni RF, Cello JP. CT imaging of colitis. Radiology. 2006;240(3):623–38. https://doi.org/10.1148/radiol.2403050818.

Article  PubMed  Google Scholar 

Kim KW, Ramaiya NH, Krajewski KM, et al. Ipilimumab-associated colitis: CT findings. AJR Am J Roentgenol. 2013;200(5):W468–74. https://doi.org/10.2214/AJR.12.9751.